Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS)
Chengdu, CN
Chengdu Easton Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the full spectrum of drug development, encompassing research, development, production, and market distribution of medicinal products. The company offers finished medications tailored for various medical disciplines, including pain management (anesthetics/analgesics), cardiovascular health, oncology, and pediatrics. Beyond ready-to-use drugs, it also manufactures active pharmaceutical ingredients (APIs) for a broader range of therapeutic areas, such as cancer treatment, heart conditions, pain relief, anti-inflammatory uses, gastrointestinal issues, antiemetics, neurological and psychiatric disorders, and urinary system ailments. Established in 2009, the firm is headquartered in Chengdu, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.15% | -3.49% | -17.55% | -11.53% | -1.48% | -13.76% | +26.50% | +37.05% | +61.93% | +4.43% | +4.43% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-1.4% Q1'26: +6.7% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+19.9% Q1'26: -14.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+17.0% ★ Q1'26: +24.2% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+22.5% ★ Q1'26: +9.3% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+16.9% ★ Q1'26: +7.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-0.8% ★ Q1'26: -2.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.50× ★ Q1'26: 0.95× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
1.12B
est: 1.15B (-2.8%)
|
1.35B
est: 1.37B (-1.8%)
|
1.33B
est: 1.33B (+0.0%)
|
1.50B
1.50B – 1.50B
+12.5% YoY
|
1.73B
1.73B – 1.73B
+15.7% YoY
|
2.03B
2.03B – 2.03B
+17.4% YoY
|
| EBITDA |
318.55M
est: 206.83M (+54.0%)
|
337.88M
est: 376.80M (-10.3%)
|
380.75M
est: 365.11M (+4.3%)
|
410.85M
410.85M – 410.85M
+12.5% YoY
|
475.26M
475.26M – 475.26M
+15.7% YoY
|
557.98M
557.98M – 557.98M
+17.4% YoY
|
| EBIT |
245.32M
est: 150.91M (+62.6%)
|
256.51M
est: 302.97M (-15.3%)
|
299.38M
est: 293.57M (+2.0%)
|
330.34M
330.34M – 330.34M
+12.5% YoY
|
382.13M
382.13M – 382.13M
+15.7% YoY
|
448.64M
448.64M – 448.64M
+17.4% YoY
|
| Net Income |
226.57M
est: 245.48M (-7.7%)
|
238.23M
est: 264.13M (-9.8%)
|
283.25M
est: 278.04M (+1.9%)
|
306.42M
306.42M – 306.42M
+10.2% YoY
|
358.55M
358.55M – 358.55M
+17.0% YoY
|
401.41M
401.41M – 401.41M
+12.0% YoY
|
| SGA |
483.43M
est: 554.18M (-12.8%)
|
552.93M
est: 583.56M (-5.2%)
|
376.46M
est: 565.47M (-33.4%)
|
636.29M
636.29M – 636.29M
+12.5% YoY
|
736.05M
736.05M – 736.05M
+15.7% YoY
|
864.16M
864.16M – 864.16M
+17.4% YoY
|
| EPS |
1.28
est: 1.40 (-8.7%)
|
1.36
est: 1.52 (-10.5%)
|
1.63
est: 1.60 (+1.9%)
|
1.76
1.76 – 1.76
+10.2% YoY
|
2.06
2.06 – 2.06
+17.0% YoY
|
2.31
2.31 – 2.31
+12.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-28 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-27 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-26 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-25 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-22 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-21 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-19 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-18 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-15 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-14 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-13 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-12 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-11 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | B | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | B | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | B | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-29 | B | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-28 | B | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-27 | B | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-24 | B | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-23 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Avinash Ramkisan Mane | Chief Scientist of Formulation Research Department & Core Technician | — | male |
| Daming Zhang | Deputy GM & Director | — | male |
| Haibin Guo | Manager of Formulation Research Department & Core Technician | — | female |
| Mingxu Yuan | GM & Director | — | male |
| Shuyun Li | Board Secretary | — | female |
| Xiao Qin Bo | Chief Financial Officer, Accounting Supervisor & Director | — | female |
| Xingyao Song | Deputy General Manager | — | male |
| Zheng Pin Guan | Deputy GM & Core Technician | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688513.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
